<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T11:12:14Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/113978" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/113978</identifier><datestamp>2026-05-15T19:45:54Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Abetov, Danysh</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair" lang="en_US">Nikitin, Alexander</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Schimenti, John</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Sethupathy, Praveen</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-01-31T21:18:26Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2024-01-31T21:18:26Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2023-05</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 13592</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 30426596</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/113978</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/8rzc-he98</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">16176656</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Prostate cancer is the most frequently diagnosed malignancy in men. Commonly used androgen deprivation therapies lead to the development of highly aggressive castration-resistant neuroendocrine prostate carcinomas (NEPC). NEPCs carry frequent alterations in genes such as MYCN, PTEN, TP53, and RB1. Recent studies showed that the plasticity of mouse prostate tumor cells may lead to de-novo neuroendocrine (NE) differentiation. Such observations are supported by mouse models based on the prostate epithelium-specific loss of Pten and Rb1, especially in conjunction with MYCN overexpression. At the same time, some NEPCs may develop from cells showing features of luminal and neuroendocrine cell differentiation, such as in the case of Trp53 and Rb1 inactivation. Using single-cell transcriptomic analysis, we show that NEPC cells deficient for Trp53 and Rb1 have distinct and similar cell subpopulations compared to NEPC associated with Pten and Rb1 loss and MYCN overexpression. This work provides the basis for future studies to understand how the differences in target cell populations may determine the mechanisms driving the initiation and clinical behavior of NEPCs. Determining the cellular heterogeneity of NEPCs should also allow the stratification of human NEPC into clinically distinct groups and contribute to the development of more effective NEPC treatment strategies.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="rights" lang="*">Attribution-NoDerivatives 4.0 International</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri" lang="*">https://creativecommons.org/licenses/by-nd/4.0/</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Neuroendocrine prostate carcinoma</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Prostate cancer</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Understanding the role of neuroendocrine cells in prostate carcinogenesis</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="relation" qualifier="localuri">https://newcatalog.library.cornell.edu/catalog/16176656</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Biochemistry, Molecular and Cell Biology</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Biochemistry, Molecular and Cell Biology</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810.2</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Abetov, Danysh</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="1fb07fcd-172e-417b-9509-159e71e827f9">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>Understanding the role of neuroendocrine cells in prostate carcinogenesis&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2023-05&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/8rzc-he98&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Abetov, Danysh&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>https://creativecommons.org/licenses/by-nd/4.0/&lt;/License>
    &lt;Keyword>Neuroendocrine prostate carcinoma&lt;/Keyword>
    &lt;Keyword>Prostate cancer&lt;/Keyword>
   	&lt;Abstract>Prostate cancer is the most frequently diagnosed malignancy in men. Commonly used androgen deprivation therapies lead to the development of highly aggressive castration-resistant neuroendocrine prostate carcinomas (NEPC). NEPCs carry frequent alterations in genes such as MYCN, PTEN, TP53, and RB1. Recent studies showed that the plasticity of mouse prostate tumor cells may lead to de-novo neuroendocrine (NE) differentiation. Such observations are supported by mouse models based on the prostate epithelium-specific loss of Pten and Rb1, especially in conjunction with MYCN overexpression. At the same time, some NEPCs may develop from cells showing features of luminal and neuroendocrine cell differentiation, such as in the case of Trp53 and Rb1 inactivation. Using single-cell transcriptomic analysis, we show that NEPC cells deficient for Trp53 and Rb1 have distinct and similar cell subpopulations compared to NEPC associated with Pten and Rb1 loss and MYCN overexpression. This work provides the basis for future studies to understand how the differences in target cell populations may determine the mechanisms driving the initiation and clinical behavior of NEPCs. Determining the cellular heterogeneity of NEPCs should also allow the stratification of human NEPC into clinically distinct groups and contribute to the development of more effective NEPC treatment strategies.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>